Poster: AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial
Lists
Only you see this
BibTeX
@inproceedings{ravandi2022poster,
author = {Farhad Ravandi and Andrew H. Wei and Hartmut Döhner and Hamid Sayar and Pau Montesinos and Hervé Dombret and Dominik Selleslag and Kimmo Porkka and Jun Ho Jang and Barry Skikne and C.L. Beach and Yu Tian and Gail J. Roboz},
title = {{Poster: AML-457 Oral Azacitidine (Oral-AZA) in Patients With Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial}},
booktitle = {Clinical},
year = {2022},
doi = {10.1016/s2152-2650(22)00743-1},
}Loading related content...